Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenalytix Plc Regulatory News (RENX)

Share Price Information for Renalytix Plc (RENX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 26.50
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 1.00 (3.846%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 26.50
RENX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) - Renalytix plc

26 Mar 2024 12:00

RNS Number : 3187I
Stifel Nicolaus Europe Limited
26 March 2024

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

1. KEY INFORMATION

(a) Name of exempt principal trader:

Stifel Nicolaus Europe Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Renalytix plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Renalytix plc

(d) Date dealing undertaken:

25 March 2024

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchases/ sales

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

0.25p Ordinary

Buy

250

33.78 GBX

33.78 GBX

0.25p Ordinary

Sell

20,518

35 GBX

34.33 GBX

(b) Cash-settled derivative transactions

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

3. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

Date of disclosure:

26 March 2024

Contact name:

Joseph Hamshare

Telephone number:

0203 465 1195

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
FERSEISAMELSEDD
Date   Source Headline
7th Jul 20207:00 amRNSHolding(s) in Company
1st Jul 20207:00 amRNSKidneyIntelX study accepted for publication
30th Jun 20207:00 amRNSUniversity of Michigan Partnership & Data Sharing
25th Jun 20207:01 amRNSProposed Board changes; Circular & Notice of GM
25th Jun 20207:00 amRNSPublic filing re. Nasdaq dual-listing and offering
12th Jun 20207:00 amRNSKidneyIntelX™ receives New York State approval
10th Jun 20208:00 amRNSConfirmation of reduction of capital
10th Jun 20207:00 amRNSPositive results of clinical validation study
20th May 202011:06 amRNSSecond Price Monitoring Extn
20th May 202011:00 amRNSPrice Monitoring Extension
20th May 20207:00 amRNSJV for COVID-19 antibody test scaled production
18th May 20207:00 amRNSProposed dual-listing on Nasdaq
15th May 20201:02 pmRNSResult of General Meeting
5th May 202010:55 amRNSRemoval of US Securities Law Restrictions
28th Apr 20207:00 amRNSUpdate re. potential demerger of FractalDx
27th Apr 20207:00 amRNSUtah Lab Facility Achieves ISO 13485 Certification
20th Apr 20207:00 amRNSKidneyIntelX used in Mount Sinai COVID-19 study
15th Apr 20207:00 amRNSProvider network agreement for KidneyIntelX™
1st Apr 20207:00 amRNSMedicare provider number
27th Mar 202010:32 amRNSHolding(s) in Company
27th Mar 20207:00 amRNSPresentation of KidneyIntelX Health Economics Data
24th Mar 20207:00 amRNSPodium Presentation and Publication for Data
3rd Mar 20207:00 amRNSHalf-year Report
26th Feb 20207:00 amRNSNotice of Results
25th Feb 20207:00 amRNSConference attendance
8th Jan 20207:00 amRNSNew commercial testing facility opens in Utah
3rd Jan 20207:00 amRNSCMS Pricing Determination becomes effective
3rd Dec 20197:00 amRNSMedicare sets US national price for KidneyIntelX
21st Nov 20197:00 amRNSGrant of Options
19th Nov 20197:00 amRNSRenalytixAI attending City Event for Kidney Health
17th Oct 20197:00 amRNSPartnership with CDPHP on KidneyIntelX
14th Oct 20197:00 amRNSBoard appointment
1st Oct 20197:00 amRNSUS CPT® reimbursement code effective
30th Sep 20194:37 pmRNSResult of AGM
30th Sep 20198:00 amRNSUpdate on non-executive director appointment
30th Sep 20197:00 amRNSPreliminary Medicare Pricing Determination
6th Sep 20194:00 pmRNSPosting of Annual Report & Accounts &Notice of AGM
3rd Sep 20197:00 amRNSFinal Results
20th Aug 20197:00 amRNSNotice of Results
6th Aug 20197:00 amRNSExpansion of Chronic Kidney Disease Advisory Board
31st Jul 20194:30 pmRNSTotal Voting Rights
29th Jul 20197:00 amRNSThomas McLain Appointed as President and CCO
23rd Jul 20196:23 pmRNSResult of Placing & Total Voting Rights
23rd Jul 20197:01 amRNSProposed Placing to raise £12.0m (c.US$15.0m)
12th Jul 20197:00 amRNSUS Exec Order on Advancing American Kidney Health
9th Jul 20197:00 amRNSPositive Interim Results for Validation Study
8th Jul 20197:00 amRNSFractalDx Positive Results Published in JASN
1st Jul 20197:00 amRNSUS CPT® Code Granted for KidneyIntelX(TM)
7th Jun 20197:00 amRNSPositive results from FractalDx study published
4th Jun 20197:00 amRNSKidneyIntelX commercial scale production milestone

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.